Literature DB >> 20718703

RAS pathways in prostate cancer - mediators of hormone resistance?

Hayley C Whitaker1, David E Neal.   

Abstract

Although not frequently mutated in prostate cancer Ras isoforms play a pivotal role in multiple pathways that have been implicated in prostate cancer progression to androgen independence. These have included growth factor and cytokine induced activation of the androgen receptor and its coregulators by post translational modification. Current evidence suggests that Ras is also required for androgen receptor activation in hormone sensitive cells. More recently Ras has been shown to work synergistically with other pathways to promote prostate tumorigenesis. We review the multiple lines of evidence implicating Ras as therapeutic target in androgen dependent and independent prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20718703     DOI: 10.2174/156800910793358005

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  7 in total

Review 1.  The changing therapeutic landscape of castration-resistant prostate cancer.

Authors:  Timothy A Yap; Andrea Zivi; Aurelius Omlin; Johann S de Bono
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

2.  Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells.

Authors:  Amrita Datta; Hogyoung Kim; Madhu Lal; Lauren McGee; Adedoyin Johnson; Ahmed A Moustafa; Jennifer C Jones; Debasis Mondal; Marc Ferrer; Asim B Abdel-Mageed
Journal:  Cancer Lett       Date:  2017-08-24       Impact factor: 8.679

Review 3.  Evolution of androgen receptor targeted therapy for advanced prostate cancer.

Authors:  Yien Ning Sophia Wong; Roberta Ferraldeschi; Gerhardt Attard; Johann de Bono
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

4.  Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.

Authors:  Ahva Shahabi; Juan Pablo Lewinger; Jie Ren; Craig April; Andy E Sherrod; Joseph G Hacia; Siamak Daneshmand; Inderbir Gill; Jacek K Pinski; Jian-Bing Fan; Mariana C Stern
Journal:  Prostate       Date:  2016-06-08       Impact factor: 4.012

5.  Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.

Authors:  Liwei Lang; Chloe Shay; Xiangdong Zhao; Yong Teng
Journal:  J Exp Clin Cancer Res       Date:  2017-08-23

6.  High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer.

Authors:  Amrita Datta; Hogyoung Kim; Lauren McGee; Adedoyin E Johnson; Sudha Talwar; Juan Marugan; Noel Southall; Xin Hu; Madhu Lal; Debasis Mondal; Marc Ferrer; Asim B Abdel-Mageed
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379

7.  pathfindR: An R Package for Comprehensive Identification of Enriched Pathways in Omics Data Through Active Subnetworks.

Authors:  Ege Ulgen; Ozan Ozisik; Osman Ugur Sezerman
Journal:  Front Genet       Date:  2019-09-25       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.